We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+2.39%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$48.5M
Cap. Flow
+$46.9M
Cap. Flow %
25.9%
Top 10 Hldgs %
98.25%
Holding
13
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$43.9M
2
RGLS
Regulus Therapeutics
RGLS
+$3.02M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 43.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNA
1
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$34.9M 19.23%
6,213,924
– –
DRNA
2
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$33.3M 18.38%
+1,182,196
New +$43.9M
SUPN icon
3
Supernus Pharmaceuticals
SUPN
$2.78B
$32.1M 17.74%
3,600,000
– –
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$32.1M 17.73%
1,240,912
– –
AMRN
5
Amarin Corp
AMRN
$292M
$14.6M 8.08%
404,374
– –
CEMP
6
DELISTED
Cempra, Inc.
CEMP
$8.24M 4.55%
714,285
– –
ACHV icon
7
Achieve Life Sciences
ACHV
$667M
$7.09M 3.91%
274
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$6.63M 3.66%
291,902
– –
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.07M 3.35%
102,200
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$2.94M 1.62%
+2,728
New +$3.02M
HPTX
11
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.61M 0.89%
62,500
– –
ANTH
12
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.47M 0.81%
54,749
– –
ZLCS
13
DELISTED
ZALICUS INC COM NEW
ZLCS
$96K 0.05%
78,966
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2014 Portfolio in Review

As of Q1 2014, Abingworth held 13 positions worth $181M, up 37% from $133M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Abingworth deployed $46.9M of net new capital in Q1 2014, opening 2 new positions. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 1,182,196 shares worth $33.3M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier.

  • Abingworth's largest Q1 2014 buy was Dicerna Pharmaceuticals, Inc.: 1,182,196 shares worth $33.3M.
  • Abingworth's ten largest holdings make up 98% of its $181M portfolio in Q1 2014.
  • Abingworth opened 2 new positions and closed 0 in Q1 2014.
  • Abingworth's portfolio value rose 37% quarter-over-quarter to $181M.

Based on Abingworth's 13F filing for Q1 2014, filed 21 May 2014.